10550483

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified

```
                  prophetic substances identified in new Japanese-
                  language patents
 NEWS 26  OCT 07  EPFULL enhanced with full implementation of EPC2000
 NEWS 27  OCT 07  Multiple databases enhanced for more flexible patent
                  number searching

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:12:25 ON 15 OCT 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:12:36 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 OCT 2008  HIGHEST RN 1061458-09-0
DICTIONARY FILE UPDATES:  14 OCT 2008  HIGHEST RN 1061458-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.
```

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10550483.str

chain nodes :
10 11 13
ring nodes :
1 2 3 4 5 6 7
chain bonds :
1-10 5-13 6-11
ring bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-7 6-7
exact/norm bonds :
1-5 1-10 2-3 3-4 3-6 4-5 4-7 5-13 6-7 6-11
exact bonds :
1-2
isolated ring systems :
containing 1 :

G1:Ph,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 10:CLASS 11:CLASS
13:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Ph,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:12:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 102 TO ITERATE

100.0% PROCESSED 102 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1435 TO 2645
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:13:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1871 TO ITERATE

100.0% PROCESSED 1871 ITERATIONS 56 ANSWERS
SEARCH TIME: 00.00.01

L3 56 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'HCAPLUS' ENTERED AT 16:13:05 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Oct 2008 VOL 149 ISS 16
FILE LAST UPDATED: 14 Oct 2008 (20081014/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 3 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:615194 HCAPLUS
DOCUMENT NUMBER: 148:554103
TITLE: Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
INVENTOR(S): Farina, Carlo; Ghelardini, Carla; Petrillo, Paola
PATENT ASSIGNEE(S): Brane Discovery S.r.l., Italy
SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008058988	A1	20080522	WO 2007-EP62323	20071114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1925304 A1 20080528 EP 2006-124142 20061115

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: EP 2006-124142 A 20061115

AB The use of compound 1-(4-methylphenyl)dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione (I) in treating and/or preventing chemotherapy-induced peripheral neurotoxicity (CIPN) is described. The invention includes pharmaceutical compns. wherein the compound I is present in a mixture with anticancer agents. An improved anticancer treatment with reduced CIPN-related side effects is also provided. Thus, racemic I (NiK-13317) was prepared by reaction of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione with 1-iodo-4-methylbenzene. Neuroprotective effects of NiK-13317 were observed in a rat model of peripheral neuropathy induced by vincristine, paclitaxel and oxaliplatin.

IT 1020410-89-2P, NiK 16140

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(NiK 16140; preparation and cytoprotective activity of pyrroloimidazoledione derivative against antitumor agent-induced peripheral neurotoxicity)

RN 1020410-89-2 HCAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)-, (7aS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 770730-86-4P 1020410-90-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and cytoprotective activity of pyrroloimidazoledione derivative against antitumor agent-induced peripheral neurotoxicity)

RN 770730-86-4 HCAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)- (CA INDEX NAME)



RN 1020410-90-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)-, (7aR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2008:413910 HCAPLUS
DOCUMENT NUMBER:	148:462516
TITLE:	Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain
AUTHOR(S):	Farina, Carlo; Gagliardi, Stefania; Ghelardini, Carla; Martinelli, Marisa; Norcini, Monica; Parini, Carlo; Petrillo, Paola; Ronzoni, Silvano
CORPORATE SOURCE:	Brane Discovery, Gerenzano, Varese, 21040, Italy
SOURCE:	Bioorganic & Medicinal Chemistry (2008), 16(6), 3224-3232 CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER:	Elsevier Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 148:462516

GI



I

AB Chemical modifications of dimiracetam (I), a bicyclic analog of the nootropic drug piracetam, afforded a small set of novel derivs. that were investigated in in vivo models of neuropathic pain. Compds. 5, 7 and 8 displayed a very promising antihyperalgesic profile in rat models of neuropathic pain induced by both chronic constriction injury of the sciatic nerve and streptozotocin. The compds. completely reverted the reduction of pain threshold evaluated by the paw pressure test. Importantly these derivs. did not induce any behavioral impairment as evaluated by the rotarod test. These results suggest that compds. 5, 7 and 8 might represent novel and well-tolerated therapeutic agents for the relief of neuropathic pain.

IT 770730-81-9P 770730-82-0P 770730-85-3P
770730-86-4P 770730-87-5P 770730-88-6P
770730-89-7P 770730-90-0P 770730-91-1P
770730-92-2P 770730-93-3P 770730-94-4P
770730-95-5P 770730-96-6P 770730-97-7P
770730-98-8P 770730-99-9P 770731-00-5P
770731-02-7P 770731-03-8P 770731-07-2P
770731-08-3P 770731-12-9P 770731-13-0P
770731-14-1P 770731-15-2P 770731-16-3P
770731-17-4P 770731-18-5P 770731-19-6P
770731-23-2P 770731-24-3P 1020410-82-5P
1020410-83-6P 1020410-84-7P 1020410-85-8P
1020410-86-9P 1020410-87-0P 1020410-88-1P
1020410-89-2P 1020410-90-5P 1020410-91-6P
1020410-92-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(dimiracetam derivs. for treatment of neuropathic pain)

RN 770730-81-9 HCAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-phenyl- (CA INDEX NAME)



RN 770730-82-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-methylphenyl)-
(CA INDEX NAME)



RN 770730-85-3 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-methylphenyl)-
(CA INDEX NAME)



RN 770730-86-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)-
(CA INDEX NAME)



RN 770730-87-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(5-fluoro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 770730-88-6 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3-fluoro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 770730-89-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770730-90-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(4-chloro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 770730-91-1 HCAPLUS

CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3-chlorophenyl)dihydro-
(CA INDEX NAME)



RN 770730-92-2 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-methoxyphenyl)-
(CA INDEX NAME)



RN 770730-93-3 HCAPLUS
CN Benzonitrile, 3-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA
INDEX NAME)



RN 770730-94-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(4-chlorophenyl)dihydro-
(CA INDEX NAME)



RN 770730-95-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-hydroxyphenyl)-
(CA INDEX NAME)



RN 770730-96-6 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770730-97-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770730-98-8 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methoxyphenyl)- (CA INDEX NAME)



RN 770730-99-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3,5-dimethylphenyl)dihydro- (CA INDEX NAME)



RN 770731-00-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3,4-dimethylphenyl)dihydro- (CA INDEX NAME)



RN 770731-02-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 770731-03-8 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(4-chloro-3-methylphenyl)dihydro- (CA INDEX NAME)



RN 770731-07-2 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3-fluoro-5-methylphenyl)dihydro- (CA INDEX NAME)



RN 770731-08-3 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3-fluoro-4-methylphenyl)dihydro- (CA INDEX NAME)



RN 770731-12-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(4-ethylphenyl)dihydro-
(CA INDEX NAME)



RN 770731-13-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 770731-14-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[4-(hydroxymethyl)phenyl]- (CA INDEX NAME)



RN 770731-15-2 HCAPLUS
CN Benzoic acid, 4-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-16-3 HCAPLUS
CN Benzoic acid, 4-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)-, ethyl ester (CA INDEX NAME)



RN 770731-17-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 770731-18-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(4-fluorophenyl)dihydro- (CA INDEX NAME)



RN 770731-19-6 HCAPLUS
CN Benzonitrile, 4-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-23-2 HCAPLUS
CN Benzonitrile, 2-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-24-3 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3-fluorophenyl)dihydro- (CA INDEX NAME)



RN 1020410-82-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3,5-difluorophenyl)dihydro- (CA INDEX NAME)



RN 1020410-83-6 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(2-fluoro-5-methylphenyl)dihydro- (CA INDEX NAME)



RN 1020410-84-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3-chloro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 1020410-85-8 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(4-fluoro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 1020410-86-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(4-fluoro-3-methylphenyl)dihydro- (CA INDEX NAME)



RN 1020410-87-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-methylphenyl)-,
(7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1020410-88-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-methylphenyl)-, (7aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1020410-89-2 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)-, (7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1020410-90-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)-, (7aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1020410-91-6 HCAPLUS
CN Benzonitrile, 4-[(7aS)-hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 1020410-92-7 HCAPLUS
CN Benzonitrile, 4-[(7aR)-hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl]-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:817893 HCAPLUS
DOCUMENT NUMBER: 141:332191
TITLE: Preparation of new bicyclic arylimidazolones with nootropic action

INVENTOR(S): Farina, Carlo; Gagliardi, Stefania; Parini, Carlo; Martinelli, Marisa; Ghelardini, Carla
PATENT ASSIGNEE(S): Nikem Research S.r.l., Italy
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085438	A2	20041007	WO 2004-EP50339	20040322
WO 2004085438	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224087	A1	20041007	AU 2004-224087	20040322
CA 2520008	A1	20041007	CA 2004-2520008	20040322
EP 1608655	A2	20051228	EP 2004-741432	20040322
EP 1608655	B1	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008601	A	20060307	BR 2004-8601	20040322
CN 1756757	A	20060405	CN 2004-80005591	20040322
JP 2006523198	T	20061012	JP 2006-505479	20040322
NZ 543154	A	20080328	NZ 2004-543154	20040322
AT 401327	T	20080815	AT 2004-741432	20040322
MX 2005PA09903	A	20061110	MX 2005-PA9903	20050915
NO 2005004898	A	20051024	NO 2005-4898	20051024
IN 2005CN02757	A	20070525	IN 2005-CN2757	20051024
US 20070027137	A1	20070201	US 2006-550483	20060616

PRIORITY APPLN. INFO.: IT 2003-MI573 A 20030324
WO 2004-EP50339 W 20040322
OTHER SOURCE(S): CASREACT 141:332191; MARPAT 141:332191
GI



I

AB The title compds. [I; A = aryl, heteroaryl, arylalkyl; R1 = H, arylalkyl,

heterocyclylalkyl, etc.; R2 = H, alkyl, arylakyl, Ph; or R1 and R2, taken together, form a saturated carbocyclic ring; R3 = H, alkyl, aryl, arylalkyl, heterocyclyl; n = 2-4; R4 = H, alkyl, aryl, etc.] having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and antihyperalgesic action, and therefore useful for the treatment of cognitive deficits, and of various types of pain, were prepared Thus, reacting tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione with iodobenzene afforded 1-phenyl-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione which was evaluated in a rat model of mononeuropathy (data given). The pharmaceutical compns. comprising the compound I are claimed.

IT 770730-81-9P, 1-Phenyl-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione 770730-82-0P 770730-83-1P 770730-84-2P
770730-85-3P 770730-86-4P 770730-87-5P
770730-88-6P 770730-89-7P 770730-90-0P
770730-91-1P 770730-92-2P 770730-93-3P
770730-94-4P 770730-95-5P 770730-96-6P
770730-97-7P 770730-98-8P 770730-99-9P
770731-00-5P 770731-01-6P 770731-02-7P
770731-03-8P 770731-04-9P 770731-05-0P
770731-06-1P 770731-07-2P 770731-08-3P
770731-09-4P 770731-10-7P 770731-11-8P
770731-12-9P 770731-13-0P 770731-14-1P
770731-15-2P 770731-16-3P 770731-17-4P
770731-18-5P 770731-19-6P 770731-20-9P
770731-21-0P 770731-22-1P 770731-23-2P
770731-24-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrroloimidazolones with nootropic action)

RN 770730-81-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-phenyl- (CA INDEX NAME)



RN 770730-82-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-methylphenyl)- (CA INDEX NAME)



RN 770730-83-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(2,6-dimethylphenyl)dihydro- (CA INDEX NAME)



RN 770730-84-2 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-thienyl)- (CA INDEX NAME)



RN 770730-85-3 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-methylphenyl)- (CA INDEX NAME)



RN 770730-86-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methylphenyl)- (CA INDEX NAME)



RN 770730-87-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(5-fluoro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 770730-88-6 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3-fluoro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 770730-89-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770730-90-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(4-chloro-2-methylphenyl)dihydro- (CA INDEX NAME)



RN 770730-91-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3-chlorophenyl)dihydro-
(CA INDEX NAME)



RN 770730-92-2 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-methoxyphenyl)-
(CA INDEX NAME)



RN 770730-93-3 HCAPLUS
CN Benzonitrile, 3-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA
INDEX NAME)



RN 770730-94-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(4-chlorophenyl)dihydro-
(CA INDEX NAME)



RN 770730-95-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-hydroxyphenyl)-
(CA INDEX NAME)



RN 770730-96-6 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770730-97-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770730-98-8 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(4-methoxyphenyl)-
(CA INDEX NAME)



RN 770730-99-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3,5-dimethylphenyl)dihydro- (CA INDEX NAME)



RN 770731-00-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3,4-dimethylphenyl)dihydro- (CA INDEX NAME)



RN 770731-01-6 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-naphthalenyl)-
(CA INDEX NAME)



RN 770731-02-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 770731-03-8 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(4-chloro-3-methylphenyl)dihydro- (CA INDEX NAME)



RN 770731-04-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-phenyl-3-(phenylmethyl)- (CA INDEX NAME)



RN 770731-05-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-3-methyl-1-phenyl-
(CA INDEX NAME)



RN 770731-06-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-3-(2-methylpropyl)-1-phenyl- (CA INDEX NAME)



RN 770731-07-2 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
1-(3-fluoro-5-methylphenyl)dihydro- (CA INDEX NAME)



RN 770731-08-3 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3-fluoro-4-methylphenyl)dihydro- (CA INDEX NAME)



RN 770731-09-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-7a-methyl-1-phenyl- (CA INDEX NAME)



RN 770731-10-7 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-phenyl-, (7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 770731-11-8 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-phenyl-, (7aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 770731-12-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(4-ethylphenyl)dihydro-
(CA INDEX NAME)



RN 770731-13-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 770731-14-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione,
dihydro-1-[4-(hydroxymethyl)phenyl]- (CA INDEX NAME)



RN 770731-15-2 HCAPLUS
CN Benzoic acid, 4-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA
INDEX NAME)



RN 770731-16-3 HCAPLUS
CN Benzoic acid, 4-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)-, ethyl ester (CA INDEX NAME)



RN 770731-17-4 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 770731-18-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(4-fluorophenyl)dihydro- (CA INDEX NAME)



RN 770731-19-6 HCAPLUS
CN Benzonitrile, 4-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-20-9 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 770731-21-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(3-pyridinyl)- (CA INDEX NAME)



RN 770731-22-1 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 770731-23-2 HCAPLUS
CN Benzonitrile, 2-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-24-3 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3-fluorophenyl)dihydro- (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.42	202.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-2.40

FILE 'REGISTRY' ENTERED AT 16:14:51 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2008 HIGHEST RN 1061458-09-0
DICTIONARY FILE UPDATES: 14 OCT 2008 HIGHEST RN 1061458-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10550483a.str





```
chain nodes :
10  11
ring nodes :
1  2  3  4  5  6  7
chain bonds :
1-10  6-11
ring bonds :
1-2  1-5  2-3  3-4  3-6  4-5  4-7  6-7
exact/norm bonds :
1-5  1-10  2-3  3-4  3-6  4-5  4-7  6-7  6-11
exact bonds :
1-2
isolated ring systems :
containing 1 :


G1:Ph,Cy,Hy

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  10:CLASS  11:CLASS



L5      STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5                STR
```




```
G1 Ph,Cy,Hy


Structure attributes must be viewed using STN Express query preparation.


=> s 15
SAMPLE SEARCH INITIATED 16:15:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       96 TO ITERATE

100.0% PROCESSED       96 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:          1333 TO     2507
PROJECTED ANSWERS:                5 TO      234
```

```
L6            5 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 16:15:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1712 TO ITERATE

100.0% PROCESSED     1712 ITERATIONS                          104 ANSWERS
SEARCH TIME: 00.00.01

L7          104 SEA SSS FUL L5

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             178.36     381.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -2.40

FILE 'HCAPLUS' ENTERED AT 16:15:19 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Oct 2008  VOL 149 ISS 16
FILE LAST UPDATED: 14 Oct 2008  (20081014/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l6
L8            5 L6

=> s l8 and py<=2003
      24009785 PY<=2003
L9            3 L8 AND PY<=2003

=> d l8 ibib abs hitstr tot
```

L8 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:413910 HCAPLUS
DOCUMENT NUMBER: 148:462516
TITLE: Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain
AUTHOR(S): Farina, Carlo; Gagliardi, Stefania; Ghelardini, Carla; Martinelli, Marisa; Norcini, Monica; Parini, Carlo; Petrillo, Paola; Ronzoni, Silvano
CORPORATE SOURCE: Brane Discovery, Gerenzano, Varese, 21040, Italy
SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(6), 3224-3232
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:462516
GI



I

AB Chemical modifications of dimiracetam (I), a bicyclic analog of the nootropic drug piracetam, afforded a small set of novel derivs. that were investigated in in vivo models of neuropathic pain. Compds. 5, 7 and 8 displayed a very promising antihyperalgesic profile in rat models of neuropathic pain induced by both chronic constriction injury of the sciatic nerve and streptozotocin. The compds. completely reverted the reduction of pain threshold evaluated by the paw pressure test. Importantly these derivs. did not induce any behavioral impairment as evaluated by the rotarod test. These results suggest that compds. 5, 7 and 8 might represent novel and well-tolerated therapeutic agents for the relief of neuropathic pain.

IT 770730-82-0P 770730-93-3P 770731-00-5P
1020410-82-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(dimiracetam derivs. for treatment of neuropathic pain)
RN 770730-82-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-methylphenyl)-
(CA INDEX NAME)



RN 770730-93-3 HCAPLUS
CN Benzonitrile, 3-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-00-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3,4-dimethylphenyl)dihydro- (CA INDEX NAME)



RN 1020410-82-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3,5-difluorophenyl)dihydro- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:817893 HCAPLUS
DOCUMENT NUMBER: 141:332191
TITLE: Preparation of new bicyclic arylimidazolones with nootropic action

INVENTOR(S): Farina, Carlo; Gagliardi, Stefania; Parini, Carlo; Martinelli, Marisa; Ghelardini, Carla
PATENT ASSIGNEE(S): Nikem Research S.r.l., Italy
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085438	A2	20041007	WO 2004-EP50339	20040322
WO 2004085438	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224087	A1	20041007	AU 2004-224087	20040322
CA 2520008	A1	20041007	CA 2004-2520008	20040322
EP 1608655	A2	20051228	EP 2004-741432	20040322
EP 1608655	B1	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008601	A	20060307	BR 2004-8601	20040322
CN 1756757	A	20060405	CN 2004-80005591	20040322
JP 2006523198	T	20061012	JP 2006-505479	20040322
NZ 543154	A	20080328	NZ 2004-543154	20040322
AT 401327	T	20080815	AT 2004-741432	20040322
MX 2005PA09903	A	20061110	MX 2005-PA9903	20050915
NO 2005004898	A	20051024	NO 2005-4898	20051024
IN 2005CN02757	A	20070525	IN 2005-CN2757	20051024
US 20070027137	A1	20070201	US 2006-550483	20060616

PRIORITY APPLN. INFO.: IT 2003-MI573 A 20030324
WO 2004-EP50339 W 20040322
OTHER SOURCE(S): CASREACT 141:332191; MARPAT 141:332191
GI



I

AB The title compds. [I; A = aryl, heteroaryl, arylalkyl; R1 = H, arylalkyl,

heterocyclylalkyl, etc.; R2 = H, alkyl, arylakyl, Ph; or R1 and R2, taken together, form a saturated carbocyclic ring; R3 = H, alkyl, aryl, arylalkyl, heterocyclyl; n = 2-4; R4 = H, alkyl, aryl, etc.] having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and antihyperalgesic action, and therefore useful for the treatment of cognitive deficits, and of various types of pain, were prepared Thus, reacting tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione with iodobenzene afforded 1-phenyl-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione which was evaluated in a rat model of mononeuropathy (data given). The pharmaceutical compns. comprising the compound I are claimed.

IT 770730-82-0P 770730-93-3P 770731-00-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrroloimidazolones with nootropic action)

RN 770730-82-0 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-1-(2-methylphenyl)- (CA INDEX NAME)



RN 770730-93-3 HCAPLUS
CN Benzonitrile, 3-(hexahydro-2,5-dioxo-1H-pyrrolo[1,2-a]imidazol-1-yl)- (CA INDEX NAME)



RN 770731-00-5 HCAPLUS
CN 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, 1-(3,4-dimethylphenyl)dihydro- (CA INDEX NAME)



L8 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:253481 HCAPLUS
DOCUMENT NUMBER: 120:253481
ORIGINAL REFERENCE NO.: 120:44722h,44723a
TITLE: Chiral high-performance liquid chromatography of some related bicyclic lactams
AUTHOR(S): Camilleri, Patrick; Eggleston, Drake; Farina, Carlo; Murphy, Jose A.; Pfeiffer, Ugo; Pinza, Mario; Senior, Lesley A.
CORPORATE SOURCE: SmithKline Beecham, The Frythe, Welwyn Hertfordshire, AL6 9AR, UK
SOURCE: Journal of Chromatography (1993), 654(2), 207-13
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Chromatog. methods utilizing a Chiralcel OC cellulose-based column were developed for the chiral resolution of optical isomers of the cognition-enhancing ISF 4185 and related bicyclic lactams. These methods were scaled up for the preparation of purified samples of enantiomers, one pair of which was submitted to x-ray anal. The resolution of the enantiomers derived from these compds. appears to be mainly dependent on their ability to hydrogen bond to the chiral stationary phase.
IT 126101-10-8
RL: PROC (Process)
(resolution of, by chiral HPLC)
RN 126101-10-8 HCAPLUS
CN Imidazo[1,2-a]pyridine-2,5(1H,3H)-dione, tetrahydro- (CA INDEX NAME)



L8 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:191621 HCAPLUS
DOCUMENT NUMBER: 120:191621
ORIGINAL REFERENCE NO.: 120:33919a,33922a
TITLE: Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers
AUTHOR(S): Pinza, Mario; Farina, Carlo; Cerri, Alberto; Pfeiffer, Ugo; Riccaboni, Maria T.; Banfi, Silvano; Biagetti, Raffaella; Pozzi, Ottorino; Magnani, Maurizio; Dorigotti, Luciano
CORPORATE SOURCE: Res. Lab., SmithKline Beecham Farmaceutici S.p.A., Baranzate, 20021, Italy
SOURCE: Journal of Medicinal Chemistry (1993), 36(26), 4214-20
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:191621
GI



I

AB A series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, e.g. dimiracetam (I), were synthesized. These bicyclic derivs. contain both the 2-pyrrolidinone and 4-imidazolidinone nuclei, already recognized as important for cognition enhancing activity. In addition, these structures maintain the backbone of piracetam and oxiracetam with the acetamide side chain restricted in a folded conformation. Their ability to reverse scopolamine-induced amnesia was assessed in a one trial, step-through, passive avoidance paradigm. The main features observed are a potent antiamnestic activity after i.p. administration (minimal ED being between 0.3 and 1 mg/kg i.p. for most compds.), the presence of a bell-shaped dose-response curve and, generally, a reduction of biol. activity after po administration. However, the unsubstituted compound I shows no evidence of a bell-shaped dose-response curve and completely retains activity when given orally, being 10-30 times more potent than the reference drug oxiracetam.

IT 126101-10-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cognition enhancer-activity of)

RN 126101-10-8 HCAPLUS

CN Imidazo[1,2-a]pyridine-2,5(1H,3H)-dione, tetrahydro- (CA INDEX NAME)



L8 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:158246 HCAPLUS

DOCUMENT NUMBER: 112:158246

ORIGINAL REFERENCE NO.: 112:26755a,26758a

TITLE: Condensed imidazole derivatives useful as nootropic agents, a process and intermediates for their preparation, and pharmaceutical compositions containing them

INVENTOR(S): Pinza, Mario; Riccaboni, Maria Teresa; Cerri, Alberto; Farina, Carlo

PATENT ASSIGNEE(S): I.S.F. S.p.A., Italy

SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 335483	A2	19891004	EP 1989-301123	19890206
EP 335483	A3	19911218		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8900438	A	19890809	FI 1989-438	19890130
BR 8900541	A	19891003	BR 1989-541	19890203
CN 1036204	A	19891011	CN 1989-101740	19890204
DD 283393	A5	19901010	DD 1989-325551	19890206
DD 291996	A5	19910718	DD 1989-337916	19890206
US 5053422	A	19911001	US 1989-307012	19890206
ZA 8900894	A	19911030	ZA 1989-894	19890206
CA 1324378	C	19931116	CA 1989-590213	19890206
DK 8900550	A	19890809	DK 1989-550	19890207
NO 8900515	A	19890809	NO 1989-515	19890207
NO 168424	B	19911111		
NO 168424	C	19920219		
AU 8929692	A	19890810	AU 1989-29692	19890207
AU 616240	B2	19911024		
HU 53363	A2	19901028	HU 1989-574	19890207
HU 203104	B	19910528		
HU 204794	B	19920228	HU 1990-4864	19890207
SU 1799383	A3	19930228	SU 1989-4613489	19890207
JP 01246281	A	19891002	JP 1989-29571	19890208
RO 105963	B1	19930130	RO 1989-145763	19890208
RO 105964	B1	19930130	RO 1989-145764	19890208
RO 105965	B1	19930130	RO 1989-145765	19890208
RO 104070	B1	19930720	RO 1989-138146	19890208
US 5130319	A	19920714	US 1991-669806	19910315
NO 9101566	A	19890809	NO 1991-1566	19910419
AU 9179479	A	19910912	AU 1991-79479	19910701
US 5200406	A	19930406	US 1992-862855	19920403
PRIORITY APPLN. INFO.:			IT 1988-19336 A	19880208
			US 1989-307012 A3	19890206
			NO 1989-515 A1	19890207
			US 1991-669806 A3	19910315

OTHER SOURCE(S): MARPAT 112:158246

GI



I

AB Eighteen title compds. I (R1 = H, C1-4 alkyl, CHR4CONHR5, CHR4CO2R5; R2 = H, C1-5 alkyl, amino acid side chain; R3 = H, C1-4 alkyl, CONH2, CO2R6; R4-R6 = H, C1-4 alkyl; n = 2-4) were prepared as nootropics. For example, cyclocondensation of PhCH2NHCH2CONH2 with OCH(CH2)2CO2Et gave 75% Et 1-benzyl-4-oxo-2-imidazolidinepropanoate, which underwent hydrogenolysis of the benzyl group and cyclization over ion exchangers to give 67% I (R1 = R2 = R3 = H; n = 2) (II). In a passive avoidance test in rats, II and 2 addnl. I were approx. 30-fold as potent as oxiracetam in reversing scopolamine-induced amnesia.

IT 126101-10-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as nootropic agent)
RN 126101-10-8 HCAPLUS
CN Imidazo[1,2-a]pyridine-2,5(1H,3H)-dione, tetrahydro- (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.32	416.67
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-6.40

STN INTERNATIONAL LOGOFF AT 16:17:01 ON 15 OCT 2008